Kite Pharma Press Releases & News Stories Related to Relationship with National Cancer Institute

(More on government funded inventions here. Other KEI comments on NIH licenses are found here.)

Kite Pharma is a California-based biopharmaceutical company working on various types of cell therapies for the treatment of cancer, in a bid to become the first pharmaceutical firm to gain successful FDA approval for this new class of cancer treatment.

Kite closely collaborates with the National Cancer Institute, which conducted significant early research into the forms of cell therapies that Kite is seeking to commercialize. NCI conducts clinical trials under Cooperative Research and Development Agreements (CRADAs) with Kite, and additionally has granted exclusive licenses on over a dozen patents to Kite on the same technologies.

For more information on Kite’s relationship with the NIH, see here: /node/2640.

Below are selected news stories and press releases related to the development history of Kite’s pipeline, as well as its relationship with the National Institutes of Health.